SNEX vs. CORT
SNEX (StoneX Group Inc.) and CORT (Corcept Therapeutics Incorporated) are both stocks. SNEX operates in Capital Markets (Financial Services), while CORT operates in Biotechnology (Healthcare). Over the past 10 years, SNEX returned 33.48%/yr vs 31.34%/yr for CORT. At a 0.21 correlation, their price movements are largely independent.
Performance
SNEX vs. CORT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SNEX achieves a 118.84% return, which is significantly lower than CORT's 129.05% return. Over the past 10 years, SNEX has outperformed CORT with an annualized return of 33.48%, while CORT has yielded a comparatively lower 31.34% annualized return.
SNEX
- 1D
- -0.16%
- 1M
- 23.79%
- YTD
- 118.84%
- 6M
- 115.47%
- 1Y
- 145.88%
- 3Y*
- 77.18%
- 5Y*
- 49.24%
- 10Y*
- 33.48%
CORT
- 1D
- -0.25%
- 1M
- 32.36%
- YTD
- 129.05%
- 6M
- -6.34%
- 1Y
- 11.67%
- 3Y*
- 53.92%
- 5Y*
- 29.06%
- 10Y*
- 31.34%
SNEX vs. CORT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SNEX StoneX Group Inc. | 118.84% | 45.65% | 32.70% | 16.21% | 55.59% | 5.79% | 18.57% | 33.49% | -13.99% | 7.40% |
CORT Corcept Therapeutics Incorporated | 129.05% | -30.94% | 55.14% | 59.92% | 2.58% | -24.31% | 116.20% | -9.43% | -26.02% | 148.76% |
Correlation
The correlation between SNEX and CORT is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Apr 14, 2004 | 0.21 |
Fundamentals
SNEX:
$11.31B
CORT:
$8.32B
SNEX:
$7.78
CORT:
$0.41
SNEX:
17.83
CORT:
194.37
SNEX:
0.67
CORT:
96.82
SNEX:
0.05
CORT:
12.03
SNEX:
4.19
CORT:
13.05
SNEX:
$152.34B
CORT:
$769.10M
SNEX:
$47.64B
CORT:
$755.64M
SNEX:
$2.46B
CORT:
$3.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SNEX vs. CORT — Risk / Return Rank
SNEX
CORT
SNEX vs. CORT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for StoneX Group Inc. (SNEX) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SNEX | CORT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.28 | ||
| Sortino ratioReturn per unit of downside risk | +2.74 | ||
| Omega ratioGain probability vs. loss probability | 1.52 | 1.16 | +0.36 |
| Calmar ratioReturn relative to maximum drawdown | 7.02 | 0.18 | +6.84 |
| Martin ratioReturn relative to average drawdown | 17.98 | 0.33 | +17.65 |
Loading charts...
Drawdowns
SNEX vs. CORT - Drawdown Comparison
The maximum SNEX drawdown since its inception was -97.89%, roughly equal to the maximum CORT drawdown of -94.29%. Use the drawdown chart below to compare losses from any high point for SNEX and CORT.
Loading charts...
Drawdown Indicators
| SNEX | CORT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.89% | -94.29% | -3.60% |
Max Drawdown (1Y)Largest decline over 1 year | -20.91% | -64.40% | +43.49% |
Max Drawdown (3Y)Largest decline over 3 years | -20.91% | -71.85% | +50.94% |
Max Drawdown (5Y)Largest decline over 5 years | -24.07% | -71.85% | +47.78% |
Max Drawdown (10Y)Largest decline over 10 years | -48.65% | -71.85% | +23.20% |
Current DrawdownCurrent decline from peak | -0.16% | -30.21% | +30.05% |
Average DrawdownAverage peak-to-trough decline | -42.86% | -53.43% | +10.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.15% | 35.39% | -27.24% |
Volatility
SNEX vs. CORT - Volatility Comparison
The current volatility for StoneX Group Inc. (SNEX) is 12.39%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 13.61%. This indicates that SNEX experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SNEX | CORT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.39% | 13.61% | -1.22% |
Volatility (6M)Calculated over the trailing 6-month period | 30.98% | 85.06% | -54.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.87% | 77.18% | -34.31% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 35.24% | 74.59% | -39.35% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 36.55% | 67.22% | -30.67% |
Dividends
SNEX vs. CORT - Dividend Comparison
Neither SNEX nor CORT has paid dividends to shareholders.
Financials
SNEX vs. CORT - Financials Comparison
This section allows you to compare key financial metrics between StoneX Group Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNEX vs. CORT - Profitability Comparison
SNEX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, StoneX Group Inc. reported a gross profit of 45.35B and revenue of 45.76B. Therefore, the gross margin over that period was 99.1%.
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
SNEX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, StoneX Group Inc. reported an operating income of 45.32B and revenue of 45.76B, resulting in an operating margin of 99.0%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
SNEX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, StoneX Group Inc. reported a net income of 174.30M and revenue of 45.76B, resulting in a net margin of 0.4%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
Frequently Asked Questions
SNEX and CORT have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CORT has higher volatility (13.61%) compared to SNEX (12.39%). In terms of maximum drawdown, SNEX dropped -97.89% vs CORT's -94.29%.
SNEX currently has the higher Sharpe Ratio (3.43 vs 0.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SNEX and CORT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer